These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1239 related items for PubMed ID: 22827747

  • 1. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
    Bergsdorf C, Ottl J.
    Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hit finding: towards 'smarter' approaches.
    Langer T, Hoffmann R, Bryant S, Lesur B.
    Curr Opin Pharmacol; 2009 Oct; 9(5):589-93. PubMed ID: 19576852
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biophysics: for HTS hit validation, chemical lead optimization, and beyond.
    Genick CC, Wright SK.
    Expert Opin Drug Discov; 2017 Sep; 12(9):897-907. PubMed ID: 28658992
    [Abstract] [Full Text] [Related]

  • 9. Increasing the delivery of next generation therapeutics from high throughput screening libraries.
    Wigglesworth MJ, Murray DC, Blackett CJ, Kossenjans M, Nissink JW.
    Curr Opin Chem Biol; 2015 Jun; 26():104-10. PubMed ID: 25909818
    [Abstract] [Full Text] [Related]

  • 10. Which aspects of HTS are empirically correlated with downstream success?
    Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, Scheiber J, Jenkins JL, Deng Z, Hill WA, Popov M, Jacoby E, Glick M.
    Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
    [Abstract] [Full Text] [Related]

  • 11. High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.
    Heeres JT, Hergenrother PJ.
    Chem Soc Rev; 2011 Aug; 40(8):4398-410. PubMed ID: 21140010
    [Abstract] [Full Text] [Related]

  • 12. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T.
    Methods Enzymol; 2011 Aug; 493():469-85. PubMed ID: 21371602
    [Abstract] [Full Text] [Related]

  • 13. Non-stoichiometric inhibition in integrated lead finding - a literature review.
    Klumpp M.
    Expert Opin Drug Discov; 2016 Aug; 11(2):149-62. PubMed ID: 26653534
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
    Danielson UH.
    Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recent progress in fragment-based lead discovery.
    Schulz MN, Hubbard RE.
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [Abstract] [Full Text] [Related]

  • 19. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series.
    Duffy BC, Zhu L, Decornez H, Kitchen DB.
    Bioorg Med Chem; 2012 Sep 15; 20(18):5324-42. PubMed ID: 22938785
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.